Months before Vancouver-based Zymeworks agreed to license its experimental cancer treatment to Roche, the biotechnology company had already identified two Roche-linked drugs among its potential competitors.
The disclosure, contained in Zymeworks’ March 2026 annual filing, places Friday’s $813 million agreement within a broader Roche investment in treatments targeting DLL3, a protein associated with small-cell lung cancer. One of those investments already carries a potential value exceeding $1 billion.
Roche’s latest agreement gives the Swiss pharmaceutical company global development and commercialization rights to Zymeworks’ ZW209, according to Reuters.
Sponsored · Selkirk Copper Mines
Zymeworks will receive $55 million upfront and another $40 million if Roche initiates a planned dose-optimization study. The Vancouver company could collect an additional $718 million through development, regulatory, and commercial milestones, plus royalties on future sales.
In January 2025, Roche signed a separate agreement with Innovent Biologics for IBI3009, an experimental antibody-drug conjugate also targeting DLL3. The transaction provided Innovent with $80 million upfront and eligibility for up to $1 billion in milestone payments.
Together, the two agreements represent $1.893 billion in maximum potential payments, excluding royalties. Only $135 million consists of upfront consideration, with the remaining $1.758 billion tied to future development decisions and milestones.
Zymeworks’ own annual report identifies Roche/Innovent’s IBI3009 as a competing approach to ZW209. The same filing lists Chugai/Roche’s ALPS12, another DLL3-targeting T-cell engager, among competing development programs.
Sponsored · Cambria Gold Mines
The treatments differ technologically. Innovent’s IBI3009 uses an antibody-drug conjugate to deliver a cancer-killing payload. ZW209 is designed to engage immune cells through DLL3, CD3, and CD28, with the goal of improving antitumor activity through additional T-cell stimulation.
Zymeworks has reported encouraging laboratory and preclinical findings, but these have not established effectiveness in patients.
The market is not entirely experimental. Amgen received full FDA approval for its DLL3-targeting treatment Imdelltra in November 2025. The authorization covers certain adults with extensive-stage small-cell lung cancer following platinum-based chemotherapy.
In Amgen’s Phase 3 DeLLphi-304 study, median overall survival reached 13.6 months with Imdelltra, compared with 8.3 months for patients receiving standard chemotherapy.
ZW209 has yet to demonstrate comparable clinical results.
Zymeworks CEO Kenneth Galbraith told Reuters that Roche agreed to the partnership before efficacy data were available, citing the platform’s technological differentiation. The first patient is expected to enter the study before the end of 2026.
Under the agreement, Roche will assume subsequent development responsibility after Zymeworks completes dose escalation.
